Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

HCFA deputy

  • News

Executive Summary

Ruben Jose King-Shaw is the nominee for Health Care Financing Administration Deputy Administrator, HHS Secretary Thompson announces March 30. The secretary of Florida's Agency for Health Care Administration had been mentioned to head the agency (1"The Pink Sheet" Feb. 19, p. 23)

You may also be interested in...



Pfizer Florida Formula: Free Goods In Exchange For Formulary Status

Pfizer is offering Florida free goods in exchange for continued unrestricted access to its products on the state Medicaid formulary.

Pfizer Florida Formula: Free Goods In Exchange For Formulary Status

Pfizer is offering Florida free goods in exchange for continued unrestricted access to its products on the state Medicaid formulary.

Medi-Cal Expansion May Be Next Case For NACDS; Suit Filed Against Florida

NACDS expects a response by the end of April to its request that California submit a Medicaid state plan amendment for its pharmacy-level prescription drug discount program.

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS037590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By